International Assets Investment Management LLC Grows Position in Eli Lilly and Company (NYSE:LLY)

International Assets Investment Management LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 5.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 12,597 shares of the company’s stock after buying an additional 632 shares during the period. International Assets Investment Management LLC’s holdings in Eli Lilly and Company were worth $7,343,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Baystate Wealth Management LLC increased its stake in Eli Lilly and Company by 26.1% in the 3rd quarter. Baystate Wealth Management LLC now owns 953 shares of the company’s stock worth $512,000 after acquiring an additional 197 shares during the last quarter. North Point Portfolio Managers Corp OH raised its stake in Eli Lilly and Company by 13.4% during the third quarter. North Point Portfolio Managers Corp OH now owns 525 shares of the company’s stock valued at $282,000 after purchasing an additional 62 shares in the last quarter. IFM Investors Pty Ltd lifted its position in Eli Lilly and Company by 3.0% during the third quarter. IFM Investors Pty Ltd now owns 164,045 shares of the company’s stock valued at $88,113,000 after purchasing an additional 4,790 shares during the last quarter. High Note Wealth LLC grew its stake in shares of Eli Lilly and Company by 4.7% in the 3rd quarter. High Note Wealth LLC now owns 4,021 shares of the company’s stock worth $2,160,000 after buying an additional 181 shares in the last quarter. Finally, Waldron Private Wealth LLC increased its holdings in shares of Eli Lilly and Company by 0.7% in the 3rd quarter. Waldron Private Wealth LLC now owns 13,838 shares of the company’s stock worth $7,433,000 after buying an additional 95 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on LLY shares. Wells Fargo & Company lifted their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a report on Wednesday, February 21st. Barclays lifted their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 7th. The Goldman Sachs Group raised their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Finally, Citigroup increased their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $757.95.

Eli Lilly and Company Stock Up 4.3 %

Shares of Eli Lilly and Company stock opened at $766.74 on Tuesday. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The stock has a market cap of $728.72 billion, a price-to-earnings ratio of 112.92, a PEG ratio of 1.45 and a beta of 0.37. The firm’s 50-day moving average is $760.96 and its two-hundred day moving average is $673.52. Eli Lilly and Company has a 1 year low of $419.80 and a 1 year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company’s quarterly revenue was up 26.0% on a year-over-year basis. During the same period last year, the firm earned $1.62 earnings per share. As a group, research analysts expect that Eli Lilly and Company will post 13.82 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.68%. Eli Lilly and Company’s payout ratio is 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.